TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 79 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $8,000 | -61.9% | 15,825 | 0.0% | 0.00% | -66.7% |
| Q1 2019 | $21,000 | +16.7% | 15,825 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $18,000 | -59.1% | 15,825 | 0.0% | 0.00% | -40.0% |
| Q3 2018 | $44,000 | -22.8% | 15,825 | 0.0% | 0.01% | -28.6% |
| Q2 2018 | $57,000 | +16.3% | 15,825 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $49,000 | -51.0% | 15,825 | 0.0% | 0.01% | -41.7% |
| Q4 2017 | $100,000 | -7.4% | 15,825 | 0.0% | 0.01% | -14.3% |
| Q3 2017 | $108,000 | – | 15,825 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |